- Home
- NCZ vs NGNE Comparison
NCZ vs NGNE Comparison
Compare NCZ & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NCZ | NGNE |
|---|---|---|
| Founded | 2003 | 2003 |
| Country | United States | US |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 283.3M | 327.8M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | NCZ | NGNE |
|---|---|---|
| Price | $14.90 | $17.06 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $40.14 |
| AVG Volume (30 Days) | 65.6K | ★ 92.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | ★ 12.16% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $925,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.23 | $6.88 |
| 52 Week High | $14.99 | $37.27 |
Technical Indicators
Market Signals| Indicator | NCZ | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 64.23 | 43.48 |
| Support Level | $14.71 | $16.78 |
| Resistance Level | $14.93 | $17.93 |
| Average True Range (ATR) | 0.21 | 1.29 |
| MACD | 0.02 | 0.04 |
| Stochastic Oscillator | 81.83 | 31.24 |
Price Performance
Historical ComparisonAbout NCZ Virtus Convertible & Income Fund II of Beneficial Interest
Virtus Convertible & Income Fund II is a diversified, closed-end management investment company. The investment objective of the company is to provide total return through a combination of capital appreciation and high current income. Its portfolio of investments includes different sector investments such as in healthcare services, media, oil, gas, and consumable fuels and others.
About NGNE Neurogene Inc.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.